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Adoptive T cell therapies (ACT) using genetically re-
directed blood T cells have shown exceptional efficacy
in the treatment of CD19-expressing hematological malig-
nancies. In contrast, rapid progress in the development of
approaches to treat solid tumors have provided proof-of-
concept data but modest response rates due to several
immune evasion mechanisms, which contribute to tumor
tolerance. Oncolytic adenoviruses are conditionally repli-
cating, cancer cell lysing viruses that are intrinsically
immunogenic due to inherent pathogen-associated mole-
cular patterns. We hypothesized that we could employ the
tremendous immunostimulatory capacity of oncolytic ade-
noviruses to break tumor-associated tolerance to T cells
and set out to test this in a highly resistant B16.OVA
murine melanoma model.
Following adoptive transfer of T cell receptor (TCR)
engineered SIINFEKL-specific, CD8a+ enriched OT-I lym-
phocytes, control of B16.OVA tumor growth was superior
in adenovirus (Ad) treated immunocompetent C57BL/6
mice compared to control mice, even in the absence of
active oncolysis. Significant increase in tumor-infiltrating
immune cells such as CD45+ leukocytes, CD8+ lympho-
cytes and F4/80+ macrophages was seen Ad-treated
tumors, suggesting enhanced tumor immunogenicity. Sur-
prisingly, no statistically significant difference in numbers
of tumor-infiltrating OT-I cells was detected between
treatment groups either by in vivo SPECT/CT imaging or
by ex vivo flow cytometry. Instead, adenovirus infection
resulted in a pro-inflammatory tumor microenvironment
via upregulation of cytokines and chemokines including
IFN-g, CCL2, CCL3 and CCL5. In addition, Intratumoral
administration of adenovirus induced maturation of pro-
fessional CD11c+ antigen-presenting cells (APCs) both in
tumors and in tumor-draining lymph nodes. Interactions
between APCs and T cells were further supported by
increased levels of CD45-CD31-gp38+ fibroblastic reticu-
lar cells (FRCs) in dissociated tissues of Ad-treated mice
compared to control groups. Subsequently, increased
numbers of activated, IFN-g+ tumor-infiltrating CD8+
T cells (TILs) were detected in Ad-treated mice, suggest-
ing that tumor-induced T cell hypofunction was over-
come. Finally, an increase in endogenous CD8+ TILs
specific for tumor-associated antigens TRP-2 and gp100
was detected in combination treated mice, indicating
repertoire expansion following immunotherapy. Majority
of these adenovirus/ACT -treated mice rejected the
re-challenge of parental B16.F10 tumors, suggesting that
systemic, endogenous anti-tumor immunity was induced
despite local (intratumoral) injection of adenovirus.
In conclusion, combining ACT with oncolytic adeno-
virus can break both local immunosuppression and per-
ipheral tolerance of tumor-specific T cells, leading to
systemic anti-tumor immunity and enhanced therapeutic
efficacy. Importantly, these two modalities are not merely
an attractive combination, but could represent a way to
achieve “CD19-like” results in the treatment of solid
tumors.
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